Cipher Pharmaceuticals (STU:PHE) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PHE Cipher Pharmaceuticals Inc STU:PHE
89 GF Score
Price €8.70
GF Value €10.49
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

STU:PHE
89GF Score
Cipher Pharmaceuticals Inc STU:PHE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cipher Pharmaceuticals (STU:PHE) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of €8.70 is trading 17.1% below its estimated GF Value™ of €10.49. GuruFocus considers Cipher Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:PHE:

  • FFO:
  • GF Value™: €10.49 vs. price of €8.70 (17.1% below fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the STU:PHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cipher Pharmaceuticals Business Description

Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
89GF Score

Get the complete analysis for STU:PHE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.70
Price
€10.49
GF Value